Regulation of SLC1A4 and SLC1A5 in Prostate Cancer-Response.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. CircRNA ZFR promotes cell progression by regulating miR-96a-5p/SLC1A1 axis in hepatocellular carcinoma.Scientific reports · 2025
   Article
2. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.Molecular metabolism · 2024
   Review
3. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021
   Article
4. Aberrant SLC6A14 Expression Promotes Proliferation and Metastasis of Colorectal Cancer via Enhancing the JAK2/STAT3 Pathway.OncoTargets and therapy · 2021
   Article

Corrections and comments

• Comment on
  Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.2017
• Comment on
  Regulation of SLC1A4 and SLC1A5 in Prostate Cancer-Letter.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as